A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVID
Latest Information Update: 05 Jun 2025
At a glance
- Drugs Bezisterim (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms ADdRESs-LC
- Sponsors BioVie
Most Recent Events
- 15 May 2025 According to the BioVie Media Release, The Phase 2 ADDRESS-LC study is fully funded by a grant from the U.S. Department of Defense (DOD)
- 15 May 2025 According to the BioVie Media Release, company announced that the first patient has been enrollment in the Phase 2 ADDRESS-LC clinical trial. The Company anticipates topline data to be available in the first half of 2026.
- 22 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 1 Apr 2025.